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Human Melanocytes Do Not Express EGF Receptors
To the Editor:
Epidermal growth factor (EGF) and its receptor (EGFr) are
implicated in growth control of many cell types, including
melanoma. Yet, despite studies spanning over two dec-
ades, the expression of EGFr in normal melanocytes is
controversial. Whereas the preponderance of evidence
demonstrates EGFr in melanomas in situ and cultured
melanoma cells (Real et al, 1986; Elder et al, 1989; de Wit
et al, 1992; Ellis et al, 1992; Mattei et al, 1994; Huang et al,
1996), conflicting data have been presented regarding the
expression of the EGFr in normal melanocytes. Standard
texts and comprehensive reviews of melanocyte and
melanoma biology have categorically stated that EGFr is
absent from normal melanocytes (Halaban, 1990, 1994,
2000; Shih and Herlyn, 1993; Sauter and Herlyn, 1998). Yet
as recently as 2001, Gordon-Thomson and associates have
presented data arguing for not only the presence of EGFr on
human melanocytes, but for its tyrosine kinase-mediated
signaling in response to ligand (Gordon-Thomson et al,
2001). In our investigation of melanocyte migration in
response to applied electric fields (Grahn et al, 2003), we
found the question of whether or not cultured human
melanocytes express EGFr and signal in response to added
EGF ligand still unanswered.
To answer this question we isolated two strains of normal
human epidermal melanocytes (NHM) from neonatal fore-
skins as we have previously described (Grahn et al, 2003).
We probed cultured NHM for EGFr expression, using the
same anti-EGFr antibody (Ab-1, Oncogene Research,
Cambridge, Massachusetts) and staining procedures as
we previously reported for keratinocytes (Fang et al, 1999).
As shown in Fig 1A, we demonstrated EGFr in normal
human epidermal keratinocytes (NHK); however, there is no
specific EGFr immunostaining in the NHM (Fig 1B, C). To
rule out the possibility that the EGFr were not visualized as a
result of the receptor being downregulated as a function of
time in culture, as it has been reported for fibroblasts
(Shiraha et al, 2000), we evaluated melanocytes at both
early (P4) and late (P10) passage. In both early- and late-
passage melanocytes, specific EGFr immunostaining is
absent (Fig 1B, C), thereby making the likelihood of a
cultivation artifact unlikely.
Since immunocytochemical analyses are not quantita-
tive, we tested for the presence of functional EGFr in
melanocytes by analyzing the tyrosine phosphorylation of
the EGFr in response to the exogenously added receptor
ligand, EGF. The response of A431 and NHK cells (positive
controls) were compared with early and late passages of
NHM either in the presence or absence of TPA. When cell
lysates were immunoblotted (Pullar et al, 2003) with an anti-
EGFr antibody (1005, Santa Cruz Biotechnology, Santa
Cruz, California), A431 and NHK cells demonstrated a
strong signal (Fig 2A) which was virtually absent in the
lysates of NHM at either high or low passage, with or
without TPA. EGF stimulation induced EGFr tyrosine
phosphorylation (P-Tyr-100, Cell Signaling Technology,
Beverly, Massachusetts), in A431 and NHK cells (Fig 2B).
No response was inducible in the NHM cells, at either an
early or late passage or in any growth condition. We also
looked at the downstream signaling of EGF in melanocytes,
specifically examining the phosphorylation of the extra-
cellular signal-regulated kinase (ERK) (anti-p44/42 MAP
Kinase (ERK) and anti-Phospho p44/42 MAP Kinase
(p-ERK) Cell Signaling Technology, Beverly, Massachusetts),
Figure1
Immunostaining of epidermal growth factor receptor (EGFr) on cell
surface. Normal human epidermal keratinocytes (NHK) (A, D), normal
human epidermal melanocytes (NHM) passage 4 (B, E) and NHM
passage 10 (C, F) were immunostained for EGFr (panels A, B, C) and
counterstained with 4; 6-diamidino-2-phenylindote to visualize cell
nuclei (panels D, E, F). Scale bar is 20 mm.
Abbreviations: EGF, epidermal growth factor; EGFr, epidermal
growth factor receptor; ERK, extracellular signal-regulated kinase;
NHK, normal human epidermal keratinocytes; NHM, normal human
epidermal melanocytes; TPA, tetradecanoylphorbol 13-acetate
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a mitogen-activated kinase that is phosphorylated in
response to EGFr ligation (Gibson et al, 1999; Glading et
al, 2000; Kempiak et al, 2003). We found that although the
addition of exogenous EGF to cultured keratinocytes
induces a robust increase in ERK phosphorylation over
baseline, unstimulated levels (Fig 3, lanes 1 and 2), similar
downstream signaling is not observed in cultured melano-
cytes. Neither NHM cultured in the presence of TPA (Fig 3,
lanes 3 and 4) or its absence (Fig 3, lanes 5 and 6)
demonstrated increased ERK phosphorylation in response
to EGF addition.
The presence of the EGFr in normal human melanocytes
has been controversial. Greenebaum et al (1983) suggested
their presence by demonstrating specific binding of
125I-EGF to cultured normal human melanocytes—too low,
however, to fit a Scatchard analysis. Likewise, Kao and
Yu (1992) interpreted flow cytometric analysis of cultured
human melanocytes labeled using a fluorescent anti-EGFr
antibody as evidence of receptor expression. RT-PCR has
been reported to identify low levels of RNA transcripts for
EGFr in neonatal normal melanocytes as well (Mattei et al,
1994). On the other hand, using northern blot analysis
Chenevix-Trench et al (1990) did not detect any mRNA for
EGFr in neonatal melanocytes. Further, numerous immuno-
localization studies have failed to reveal positive EGFr
immunostaining in melanocytes either in vivo or in vitro (Real
et al, 1986; Elder et al, 1989; Huang et al, 1996). Studies of
functional response of melanocytes to EGF have demon-
strated little effect. One notable exception is the work of
Morelli et al (1992) and colleagues which reports an increase
(2-fold) in the migration of cultured neonatal melanocytes
exposed to the EGFr ligand TGF-a as compared with non-
stimulated controls, suggesting the presence of EGFr-
mediated signaling. But EGF does not increase cell growth,
nor [3H]thymidine incorporation in normal human melano-
cytes (Eisinger et al, 1985; Herlyn et al, 1987; Krasagakis
et al, 1995). Other EGFR ligands, such as TGF-a, also fail to
simulate melanocyte proliferation (Pittelkow and Shipley,
1989).
The work we present here supports the predominant
view that EGFr are lacking in human melanocytes. Cultured
neonatal melanocytes do not express EGFr as assessed by
immunolocalization studies, nor is there significant protein
expression as assessed by western blot. Additionally, the
work provides the evidence that melanocytes do not exhibit
EGF ligand-dependent signaling, as EGF stimulation does
not induce EGFr tyrosine phosphorylation. How can we
reconcile our findings with the recent report of Gordon-
Thomson and colleagues, that demonstrates low levels of
both EGFr and its TGF-a mediated phosphorylation in
lysates of cultured melanocytes (Gordon-Thomson et al,
2001)? That study fails to demonstrate that the analyzed cell
cultures are free of contaminating keratinocytes or fibro-
blasts. Thus, it is likely that a small number of contaminating
EGFr-bearing cells are included cell lysates probed by
immunoblot, and account for the low levels of EGFr and
EGR-mediated signaling detected. Additionally, the results
may have been biased by inclusion of TPA in the culture
medium, as is commonly employed for melanocyte cultiva-
tion (Eisinger et al, 1985; Herlyn et al, 1987; Pittelkow and
Shipley, 1989; Halaban, 1994, 2000). TPA can alter EGFR
expression and ligand binding, resulting in an increase in
EGF-mediated signaling and function (Matsui et al, 1993;
Sedlak et al, 1994; Xue et al, 1996). For that reason, for this
study, some experiments were performed on human
melanocytes cultivated in the absence of TPA. We found
that EGFR signaling is also absent in these cells. These
findings, along with cited earlier studies, should definitively
resolve the controversy of the EFGr in normal human
melanocytes. They are absent, and no EGF-mediated
signaling can be elicited.
Jennifer C. Grahn and R. Rivkah Isseroff
Department of Dermatology, University of California, Davis, USA
This work was supported in part by grants from the Shriners Hospitals
for Children (grant #8310) and from the NIH (AR 44518). The authors
thank Merle Reyes and Bob Sharmin for assistance in culturing
melanocytes.
Figure 2
Epidermal growth factor (EGF) does not induce epidermal growth
factor receptor (EGFr) phosphorylation in melanocytes. Cells were
stimulated with EGF 10 ng per mL for 10 min (indicated by þ ) or not
(indicated by ). Cells were grown in the presence (þ ) or absence ()
of TPA. Equal amounts of cell lysate protein (5 mg) were electrophor-
esed on a SDS-PAGE gel, transferred to a membrane and probed with
anti-EGFR (A) or anti-phosphotyrosine (B) antibody or anti-actin
(loading control) (C). Proteins were visualized by enhanced chemilumi-
nescent. Location of the EGFR is shown on the right.
Figure3
Epidermal growth factor (EGF) does not induce extracellular
signal-regulated kinase (ERK) phosphorylation in melanocytes.
Cells were stimulated with EGF 10 ng per mL for 10 min (indicated by
þ ) or not (indicated by ). Cells were grown in the presence (þ ) or
absence () of TPA. Cell lysates were electrophoresed on a SDS-PAGE
gel, transferred to a membrane and probed with anti-phospho-p44/42
MAPK (p-ERK) (A) or anti-p44/42 MAPK (ERK) (B). Proteins were
visualized by enhanced chemiluminescent.
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